In a clinical trial of COVID-19 patients admitted to UT Health San Antonio and University Health, the combination of baricitinib and remdesivir reduced recovery time, according to results released on December 11. understood. New England Journal of Medicine.. Six researchers at UT Health San Antonio and University Health are co-authors of this publication because a significant number of patients at the San Antonio site are enrolled in the trial.
Indicational COVID-19 treatment study 2 (ACTT-2) comparing combination therapy with remdesivir and active placebo in hospitalized COVID-19 patients is from the National Institute of Allergy and Infectious Diseases (NIAID). The National Institute of Health, which is part of it.
Importantly, patients using hyperoxygen by nasal cannula or receiving masked breathing assistance when enrolled in the study had 18 days on remdecibir plus placebo. , I had time to recover 10 days with the combination therapy.
The researchers also found differences in patient survival. The 28-day mortality rate was 5.1% in the combination therapy group and 7.8% in the remdesivir placebo group.
“We are advancing the treatment of COVID-19,” said Joe R. of UT Health San Antonio and Dr. Tomas Patterson, MD, professor and director of infectious diseases at Teresa Rosanolong School of Medicine. It was. “Remdesivir significantly improved recovery in critically ill patients in the first ACTT study, and baricitinib further helped patients in this second study.”
Remdesivir is a direct-acting antiviral drug, while baricitinib is an anti-inflammatory drug.
“I think this combination is good for several reasons,” said Dr. Patterson. “Baricitinib, in contrast to other anti-inflammatory drugs, has its own activity against the virus. Second, it is a fairly specific inhibitor of inflammation.”
Baricitinib is approved for the treatment of patients with active rheumatoid arthritis. The U.S. Food and Drug Administration issued an emergency use of baricitinib in combination with remdesivir on November 19, 2020 for suspected or laboratory-confirmed treatment of COVID-19 in hospitalized adults and pediatric patients aged 2 years and older. I have issued a permit. Requires oxygenation, invasive ventilation or extracorporeal membrane oxygenation.
We conduct these clinical trials to achieve our goals. It is to save lives. At the beginning of the pandemic, we are approaching our goal as we have lost many of the patients we are currently saving. “
Dr. Thomas Patterson, Joe R. and Teresa Rosano Long School of Medicine, Professor and Chief of Infectious Diseases at UT Health San Antonio
University of Texas San Antonio Health Science Center
Karil, AC, et al. (2020) Baricitinib and remdesivir for inpatient adults by Covid-19. The New England Journal of Medicine. doi.org/10.1056/NEJMoa2031994.
Combination therapy reduces recovery time in COVID-19 patients, clinical trials discover
Source link Combination therapy reduces recovery time in COVID-19 patients, clinical trials discover